← Eichor
Condition: Refractory Hepatocellular Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Hepatocellular Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Phase 1/Phase 2 · 4 location(s) · Eureka Therapeutics Inc. · NCT04634357Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Phase 1/Phase 2 · 2 location(s) · St. Jude Children's Research Hospital · NCT05468359A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Phase 1 · 2 location(s) · LaunXP Biomedical Co., Ltd. · NCT06883539Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Soli
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT06620302AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Phase 1 · 2 location(s) · University of Southern California · NCT05791448Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT04803318Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Phase 1 · 1 location(s) · West China Hospital · NCT07106827Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
Phase 2 · 1 location(s) · Shunda Du · NCT07639138Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Phase 2 · 5 location(s) · Allison O'Neill, MD · NCT04134559Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/Phase 2 · 3 location(s) · GV20 Therapeutics · NCT07070518A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · Eastern Hepatobiliary Surgery Hospital · NCT06902389Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119Ligufalimab and Cadonilimab in Advanced Liver Cancers
Phase 2 · 1 location(s) · University of Texas Southwestern Medical Center · NCT06789848PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT07018518Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05608213IDOV-Immune for Advanced Solid Tumors
Phase 1 · 5 location(s) · ViroMissile, Inc. · NCT06910657Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06904196Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07500220
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.